Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Tyfast has raised a total of US$1M in this financing round. Proceeds will be utilised by Tyfast to scale up commercialisation activities for this breakthrough battery technology that uses vanadium to make its proprietary anode. Further, the company is developing its vanadium technology to be a drop-in replacement for standard-graphite anodes in lithium-ion battery manufacturing to allow direct integration into existing manufacturing lines for rapid commercialisation.
https://www.lse.co.uk/SharePrice.asp?shareprice=NMT&share=Neometals
Tyfast has raised a total of US$1M in this financing round. Proceeds will be utilised by Tyfast to scale up commercialisation activities for this breakthrough battery technology that uses vanadium to make its proprietary anode. Further, the company is developing its vanadium technology to be a drop-in replacement for standard-graphite anodes in lithium-ion battery manufacturing to allow direct integration into existing manufacturing lines for rapid commercialisation.
https://www.lse.co.uk/SharePrice.asp?shareprice=NMT&share=Neometals
Vanadium is a critical raw material according to the European Commission and features superior energy density compared to other battery materials. It is fast becoming recognised as a significant addition to new lithium-ion cathode and anode chemistries used in electric vehicles as well as in VRFBs used for long duration energy storage solutions from renewable sources. Currently, approximately 75% of global vanadium supply is sourced from China, South Africa, and Russia.
https://finance.yahoo.com/news/win-win-europe-mineral-processing-070000210.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAFWIO_5CCx9MHK9OCab6WfQbvQ2gLo-HpnQY6McGU8iUamX57YonO-ka6E4zP1RmvTHj9LFSlbvAw_fPR3e23v8IMbnYhEEuGb1QyuEoT4KImFHIBtamdnbzIgh_Wrfu9RgxPtjuyBjZKX51TRUw2fL0-wfMpJcPgt5AkVBFNPpJ
kevkan
I think only a consultant in the ICU can get SNG001 via the MAP. They could try to get hold of the consultant in the local hospital and tell him their fears and certainly if he goes into hospital just refuse to take no for an answer. If you say you will pay for it, you may meet less resistance.....
theboyg
They are not in a position to talk about Act 2 P2 until results are known not their trial. However assuming we graduate to Active P3 it will target hospitalised and hopefully breathless on a global platform which for me speaks volumes.
Nothing more to add
Part 2 of the trial, was designed to study the efficacy and safety of inhaled SNG001 in up to 120 COPD patients with a confirmed respiratory viral infection, commenced in October 2018, and recruitment into the trial commenced in earnest in January 2019.
In March 2019 the Data Safety Monitoring Committee (DSMC) completed its planned safety review of Part 2 of the trial. In its review, the DSMC did not identify any safety concerns for patients currently enrolled and it endorsed a pre-planned broadening of the patient population to allow patients with more severe COPD to participate in the trial.